Loading clinical trials...
Loading clinical trials...
Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis
Conditions
Interventions
Bimagrumab
Placebo
Locations
38
United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Orange, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Kansas City, Kansas, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Start Date
November 2, 2015
Primary Completion Date
August 17, 2016
Completion Date
February 13, 2017
Last Updated
March 13, 2018
NCT06479863
NCT04421677
NCT01423110
NCT02735447
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions